

amyloid monoclonal antibody [with heparan-like characteristics]. In a further preferred embodiment, the expression vector includes the sequence for the single chain monoclonal antibody of the above anti- β -amyloid mAb.

In the ABSTRACT, please amend as follows:

A method of selecting anti-aggregation molecules with chaperone-like activity that have characteristics including binding to a native target molecule epitope with a high binding constant and are non-inhibitory to the biological activity of the target molecule. The method [molecules denaturing] involves denaturing a target molecule in the presence of [presumptative] presumptive antiaggregation molecules to prevent the target molecules from self-or induced-aggregation. The nonaggregated target molecule coupled to the anti-aggregation molecule is then tested for bioactivity.

IN THE CLAIMS

Please cancel Claims 126-149 without prejudice to the continuation of prosecution thereof in a divisional application.

Please insert new claims 150-167 as follows:

150. A pharmaceutical formulation, comprising:

(A) an antibody or antigen binding fragment thereof,

wherein:

(i) said antibody and said fragment recognize an epitope within residues 1-28 of beta-amyloid, and

(ii) said antibody and said fragment inhibit aggregation of beta-amyloid; and

(B) a pharmaceutically acceptable carrier.

151. The pharmaceutical formulation of claim 150, wherein said antibody is a monoclonal antibody.

152. The pharmaceutical formulation of claim 151, wherein said antibody is a human monoclonal antibody.

153. The pharmaceutical formulation of claim 151, wherein said antibody is a genetically-engineered monoclonal antibody.

154. The pharmaceutical formulation of claim 153, wherein said antibody is a single-chain antibody.

155. The pharmaceutical formulation of any one of claims 150-154, wherein said beta-amyloid is human beta-amyloid.

156. A pharmaceutical formulation, comprising:

(A) an antibody or antigen binding fragment thereof,
wherein:

(i) said antibody is obtainable using residues 1-28 of beta-amyloid as an immunogen, and

(ii) said antibody and said fragment inhibit aggregation of beta-amyloid; and

(B) a pharmaceutically acceptable carrier.

157. The pharmaceutical formulation of claim 156, wherein said antibody is a monoclonal antibody.

158. The pharmaceutical formulation of claim 157, wherein said antibody is a human monoclonal antibody.

159. The pharmaceutical formulation of claim 157, wherein said antibody is a genetically-engineered monoclonal antibody.

160. The pharmaceutical formulation of claim 159, wherein said antibody is a single-chain antibody.

161. The pharmaceutical formulation of any one of claims 156-160, wherein said beta-amyloid is human beta-amyloid.

162. A pharmaceutical formulation, comprising:

(A) an antibody or antigen binding fragment thereof, wherein:

(i) said antibody and said fragment recognize an epitope within residues 1-28 of beta-amyloid, and

(ii) said antibody and said fragment maintain the solubility of soluble beta-amyloid; and

(B) a pharmaceutically acceptable carrier.

163. The pharmaceutical formulation of claim 162, wherein said antibody is a monoclonal antibody.

164. The pharmaceutical formulation of claim 163, wherein said antibody is a human monoclonal antibody.